

# Arden R Barry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2532415/publications.pdf>

Version: 2024-02-01

74  
papers

1,746  
citations

567247

15  
h-index

289230

40  
g-index

77  
all docs

77  
docs citations

77  
times ranked

2771  
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	1.7	775
2	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology, 2021, 37, 1129-1150.	1.7	367
3	A Systematic Review of the Effect of CYP3A5 Genotype on the Apparent Oral Clearance of Tacrolimus in Renal Transplant Recipients. Therapeutic Drug Monitoring, 2010, 32, 708-714.	2.0	65
4	Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. Canadian Family Physician, 2016, 62, 32-7.	0.4	36
5	Patients'™ perceptions and use of natural health products. Canadian Pharmacists Journal, 2018, 151, 254-262.	0.8	32
6	Assessment of atrial fibrillation patients' education needs from patient and clinician perspectives: A qualitative descriptive study. Thrombosis Research, 2019, 173, 109-116.	1.7	29
7	Omega-3 polyunsaturated fatty acid supplementation in the prevention of cardiovascular disease. Canadian Pharmacists Journal, 2016, 149, 166-173.	0.8	27
8	Long-term Beta-blocker Therapy after Myocardial Infarction in the Reperfusion Era: A Systematic Review. Pharmacotherapy, 2018, 38, 546-554.	2.6	26
9	An Evaluation of Teaching Physical Examination to Pharmacists. Canadian Pharmacists Journal, 2012, 145, 174-179.e1.	0.8	22
10	Pharmacotherapy for heart failure with reduced ejection fraction and health-related quality of life: a systematic review and meta-analysis. European Journal of Heart Failure, 2021, 23, 578-589.	7.1	22
11	Professional Use of Social Media by Pharmacists. Canadian Journal of Hospital Pharmacy, 2015, 68, 22-7.	0.1	21
12	Longitudinal Oral Anticoagulant Adherence Trajectories in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2021, 78, 2395-2404.	2.8	21
13	Case report and review of clenbuterol cardiac toxicity. Journal of Cardiology Cases, 2013, 8, 131-133.	0.5	20
14	Pharmacotherapy of Heart Failure with Preserved Ejection Fraction. Pharmacotherapy, 2015, 35, 351-360.	2.6	19
15	Prevention and management of statin adverse effects: A practical approach for pharmacists. Canadian Pharmacists Journal, 2018, 151, 179-188.	0.8	19
16	Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis. Current Diabetes Reviews, 2018, 14, 273-279.	1.3	16
17	Primary Prevention of Cardiovascular Disease in Older Adults. Canadian Journal of Cardiology, 2016, 32, 1074-1081.	1.7	15
18	Influenza Vaccination for Secondary Prevention of Cardiovascular Events: A Systematic Review. Canadian Journal of Hospital Pharmacy, 2017, 70, 27-34.	0.1	15

#	ARTICLE	IF	CITATIONS
19	A Systematic Review of Add-on Pharmacologic Therapy in the Treatment of Resistant Hypertension. American Journal of Cardiovascular Drugs, 2017, 17, 311-318.	2.2	14
20	Assessment of Condition and Medication Knowledge Gaps Among Atrial Fibrillation Patients: A Systematic Review and Meta-analysis. Annals of Pharmacotherapy, 2019, 53, 773-785.	1.9	14
21	Clozapine-Associated Myocarditis: Case Report and Literature Review. Canadian Journal of Hospital Pharmacy, 2015, 68, 427-9.	0.1	12
22	Reasons for non-use of proven pharmacotherapeutic interventions: systematic review and framework development. Journal of Evaluation in Clinical Practice, 2012, 18, 49-55.	1.8	10
23	Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease. Pharmacotherapy, 2021, , .	2.6	10
24	<b>Evaluation of Preventive Cardiovascular Pharmacotherapy after Coronary Artery Bypass Graft Surgery</b>. Pharmacotherapy, 2014, 34, 464-472.	2.6	9
25	Patient Satisfaction with Services Provided by Multidisciplinary Anticoagulation Clinics. Pharmacotherapy, 2013, 33, 1246-1251.	2.6	7
26	Adverse drug reactions. Canadian Pharmacists Journal, 2014, 147, 233-238.	0.8	7
27	Applying the guidelines for pharmacists integrating into primary care teams. Canadian Pharmacists Journal, 2016, 149, 219-225.	0.8	7
28	Coenzyme Q10 supplementation in the management of statin-associated myalgia. American Journal of Health-System Pharmacy, 2017, 74, 786-793.	1.0	7
29	Short- versus standard-term dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: A meta-analysis. Journal of Cardiology, 2017, 69, 353-358.	1.9	7
30	Single vs Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Implantation: A Systematic Review. Clinical Cardiology, 2015, 38, 629-634.	1.8	6
31	Treatment of chronic noncancer pain in patients on opioid therapy in primary care: A retrospective cohort study. Canadian Pharmacists Journal, 2020, 153, 52-58.	0.8	6
32	Triple antithrombotic therapy in patients with atrial fibrillation who have undergone percutaneous coronary intervention with stent implantation. American Journal of Health-System Pharmacy, 2012, 69, 1485-1493.	1.0	5
33	DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics. Canadian Journal of Hospital Pharmacy, 2016, 69, 253-4.	0.1	5
34	Cardiovascular safety outcomes of new antidiabetic therapies. American Journal of Health-System Pharmacy, 2017, 74, 970-976.	1.0	5
35	Perceptions of Independent Pharmacist Prescribing among Health Authority- and Community-Based Pharmacists in Northern British Columbia. Pharmacy (Basel, Switzerland), 2021, 9, 92.	1.6	5
36	Evaluation of Physical Assessment Education for Practising Pharmacists: A Cross-Sectional Survey. Canadian Journal of Hospital Pharmacy, 2019, 72, 27-33.	0.1	5

#	ARTICLE	IF	CITATIONS
37	Review of the top 5 cardiology studies of 2011-12. Canadian Pharmacists Journal, 2013, 146, 213-217.	0.8	4
38	Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention. Canadian Journal of Hospital Pharmacy, 2016, 69, 280-5.	0.1	4
39	Development of a Pharmacist REferral Program in a primary cARE clinic (PREPARE): A prospective cross-sectional study. Canadian Pharmacists Journal, 2017, 150, 206-215.	0.8	4
40	Evaluation of Physical Assessment Education for Practising Pharmacists: A Cross-Sectional Survey. Canadian Journal of Hospital Pharmacy, 2019, 72, .	0.1	4
41	Reasons for Non-use of Proven Interventions for Hospital Inpatients: Pharmacists's Perspectives. Canadian Journal of Hospital Pharmacy, 2009, 62, 381-5.	0.1	3
42	Review of the top 5 cardiology studies of 2013-14. Canadian Pharmacists Journal, 2015, 148, 349-354.	0.8	3
43	Physical assessment educational programs for pharmacists and pharmacy students: A systematic review. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 211-223.	1.0	3
44	Colchicine for Secondary Cardiovascular Prevention: A Systematic Review. Pharmacotherapy, 2020, 40, 575-583.	2.6	3
45	Therapeutic Controversies in the Medical Management of Valvular Heart Disease. Annals of Pharmacotherapy, 2021, 55, 1379-1385.	1.9	3
46	Pharmacist- or Nurse Practitioner-Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. Canadian Journal of Hospital Pharmacy, 2020, 73, 186-192.	0.1	3
47	Making Hospital Pharmacists Indispensable on the Healthcare Team: Revolution in Waiting. Journal of Pharmacy Practice and Research, 2009, 39, 256-257.	0.8	2
48	Review of the top 5 cardiology studies of 2015-16. Canadian Pharmacists Journal, 2017, 150, 380-386.	0.8	2
49	Review of the top 5 cardiology studies of 2017-18. Canadian Pharmacists Journal, 2020, 153, 32-36.	0.8	2
50	COVID-19 and the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Canadian Pharmacists Journal, 2020, 153, 193-197.	0.8	2
51	Anticoagulant Utilization and Direct Oral Anticoagulant Prescribing in Patients with Nonvalvular Atrial Fibrillation. Canadian Journal of Hospital Pharmacy, 2019, 72, 428-434.	0.1	2
52	Managing Heart Failure With Reduced Ejection Fraction in Patients With Chronic Kidney Disease: A Case-Based Approach and Contemporary Review. CJC Open, 2022, 4, 802-809.	1.5	2
53	What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation?. American Journal of Health-System Pharmacy, 2016, 73, e229-e237.	1.0	1
54	Patient-Centred Care through Storytelling. Canadian Journal of Hospital Pharmacy, 2017, 70, 322-323.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Coenzyme Q10 for statin-associated myalgia. American Journal of Health-System Pharmacy, 2018, 75, 15-15.	1.0	1
56	Anticoagulant Utilization and Direct Oral Anticoagulant Prescribing in Patients with Nonvalvular Atrial Fibrillation. Canadian Journal of Hospital Pharmacy, 2019, 72, .	0.1	1
57	The case for independent pharmacist prescribing. Canadian Pharmacists Journal, 2020, 153, 319-320.	0.8	1
58	Developments in Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 2215.	7.4	1
59	Use of low-dose acetylsalicylic acid for cardiovascular disease prevention: A practical, stepwise approach for pharmacists. Canadian Pharmacists Journal, 2020, 153, 153-160.	0.8	1
60	â€˜The bus analogyâ€™: A new analogy to help pharmacy students conceptualize the well-stirred model. Currents in Pharmacy Teaching and Learning, 2017, 9, 639-643.	1.0	1
61	Primary care and the RCMP: Unexpected partnership in opioid harm reduction. Canadian Family Physician, 2018, 64, 489-490.	0.4	1
62	Health Authority Pharmacists' Perceptions of Independent Pharmacist Prescribing. Canadian Journal of Hospital Pharmacy, 2019, 72, 185-193.	0.1	1
63	Medication management for heart failure with reduced ejection fraction. Canadian Family Physician, 2021, 67, 915-922.	0.4	1
64	Is It Ethical for Health Care Organizations to Charge Institutions for Experiential Rotations?. Canadian Journal of Hospital Pharmacy, 2009, 62, 331-4.	0.1	0
65	One Good Note. Canadian Journal of Hospital Pharmacy, 2014, 67, 250.	0.1	0
66	Should Patients Continue to Receive Statins Once They Reach 80 Years of Age?. Canadian Journal of Hospital Pharmacy, 2017, 70, .	0.1	0
67	Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?. Canadian Journal of Hospital Pharmacy, 2018, 71, .	0.1	0
68	Newer Oral Antihyperglycemics: From Seinfeld to Breaking Bad. Canadian Journal of Hospital Pharmacy, 2019, 72, .	0.1	0
69	Comparison of Preventive Cardiovascular Pharmacotherapy in Surgical vs Percutaneous Coronary Revascularization. CJC Open, 2019, 1, 297-304.	1.5	0
70	Antiplatelet therapy with or without anticoagulant therapy for lower extremity peripheral artery disease: A systematic review. American Journal of Health-System Pharmacy, 2021, , .	1.0	0
71	Review of the top 5 cardiology studies of 2019-20. Canadian Pharmacists Journal, 2021, 154, 388-393.	0.8	0
72	Prescribing by Pharmacists and Collaborative Care: Are We Ready to Accept the Baton and Get in the Race?. Canadian Journal of Hospital Pharmacy, 2010, 63, 59.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Newer Oral Antihyperglycemics: From to. Canadian Journal of Hospital Pharmacy, 2019, 72, 385-387.	0.1	0
74	Omega-3 fatty acids for cardiovascular disease prevention: A practice tool for pharmacists. Canadian Pharmacists Journal, 2022, 155, 171516352210876.	0.8	0